Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,601 signal articles · 135 in last 24h · 155,365 total before filter · latest 2h ago
135last 24h
852last 7d
146● bullish (7d)
90● bearish (7d)
214publishers
AllMacro192Earnings102M&A125Regulatory20Product22Analyst19
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
Investing.com71d agobullish
UnitedHealth shares surge on strong earnings beat and guidance

Investing.com -- UnitedHealth Group (NYSE:UNH) reported second quarter results that exceeded analyst expectations across earnings, revenue and guidance, sending shares up 7% premarket as investors responded positively to the healthcare giant's improved outlook.

Aehr Test (AEHR) Soars as Bullish Outlook Overshadows Weak FY Earnings
Insider Monkey72d agobullish
Aehr Test (AEHR) Soars as Bullish Outlook Overshadows Weak FY Earnings

Aehr Test Systems climbed by 21.91 percent on Wednesday to close at $87.79 apiece, after management projected a sharp acceleration in its full-year growth for fiscal 2027, underpinned by a record backlog and the continued strong demand for semiconductor testing solutions in AI infrastructure. In an earnings call on Tuesday, the company said that it […]

Aehr Test Systems surge on earnings beat, strong guidance
Proactive72d agobullish
Aehr Test Systems surge on earnings beat, strong guidance

Aehr Test Systems (NASDAQ:AEHR) shares jumped 30% after the semiconductor test and burn-in equipment provider reported fiscal fourth-quarter results that exceeded Wall Street expectations and provided a stronger-than-anticipated revenue outlook for fiscal 2027. The company posted adjusted...

Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance
Proactive72d agobullish
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...